The first scientist to clone HIV asiaresearchnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaresearchnews.com Daily Mail and Mail on Sunday newspapers.
(1)
Berwyn, Pennsylvania (Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ( Annovis or the Company ), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, is presenting new clinical efficacy and biomarker data of its drug ANVS401 during a one hour panel presentation, beginning at 8:00 p.m. ET today, July 28, at the 2021 Alzheimer s Association International Conference (AAIC) in Denver, Colorado.
The first part of the panel will feature Cheng Fang, PhD, Annovis Bio s VP of Research, an expert in axonal transport and protein aggregation. Dr. Fang will present the mechanism of action and will be followed by William Mobley, PhD, Distinguished Professor, Department of Neurosciences, and the Florence Riford Chair for Alzheimer s Research at the Un
(0)
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Rudolph Tanzi, Ph.D, as Chair of the Company s scientific advisory board (SAB). Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital.
(1)
Collaborative mice study with UC San Diego to study brain development from embryo to old age
Berwyn, Pennsylvania (Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced a new research collaboration with Professor William Mobley and Dr. Xuqiao Chen at the University of California San Diego designed to study the ability of the Company s lead compound, ANVS401, to normalize brain development in Down Syndrome (DS) mice. While we know quite a bit about how the brain degenerates in the later stages of life, extraordinarily little is known about how neurodegeneration may start very early in life. We, therefore, plan to look at the brain in embryonic development in DS mice, said Maria Maccecchini, Ph.D., Founder and Chief Executive Officer.